Impact Of Patisiran On Health Status And Quality Of Life In Patients With Transthyretin Cardiac Amyloidosis

APOLLO-B is a Phase 3 study of patisiran in patients with transthyretin (ATTR) cardiac amyloidosis (NCT03997383), which demonstrated a significant benefit in functional capacity (6-MWT), and health status and quality of life (QoL) (KCCQ-OS) with patisiran vs placebo at Month (M) 12.

Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Zubair Shah, Laura Obici, Parag Kale, Sumeet S. Mitter, Per Eldhagen, Toru Hashimoto, Edileide de Barros Correia, Matthew T. White, Sean Bender, Patrick Y. Jay, Kelley Capocelli, Mazen A. Hanna Tags: 030 Source Type: research